## Abstract Rapid self‐renewal of human embryonic stem (ES) cells (NIH designation WA01 and WA09) is accommodated by an abbreviated cell cycle due to a reduction in the G1 phase. Thus, molecular mechanisms operative in ES cells may expedite the cellular commitment to progress into S phase to initia
E2F target genes and cell-cycle checkpoint control
✍ Scribed by Patrizia Lavia; Pidder Jansen-Dürr
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 97 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0265-9247
No coin nor oath required. For personal study only.
✦ Synopsis
In this review, we will focus on the role played by transcription factors of the E2F/DP family in controlling the expression of genes that carry out important cell-cycle control functions, thereby ensuring ordered progression through the mammalian cell division cycle. The emerging picture is that cell-cycle progression depends on the execution of a regulatory cascade of gene expression, driven by E2F/DP transcription factors, which are in turn regulated by the products of some of these genes. That E2F factors are potent regulators of cell-cycle checkpoints in mammalian cells is supported by experiments demonstrating that ectopic expression of individual E2F family members is sufficient to modulate cell proliferation and apoptosis. It is also clear that deregulation of E2F activity will result in the loss of particular checkpoint controls, thereby predisposing cells to malignant conversion.
📜 SIMILAR VOLUMES
## Abstract The tightly controlled network of cell cycle genes consists of a core of cyclin dependent kinases (CDKs) that are activated by periodically expressed cyclins. The activity of the cyclin‐CDK complexes is regulated by cyclin dependent kinase inhibitors (CDKIs) and multiple signal transduc
## Abstract The loss of DNA mismatch repair (MMR) is responsible for hereditary nonpolyposis colorectal cancer and a subset of sporadic tumors. Acquired resistance or tolerance to some anti‐cancer drugs occurs when MMR function is impaired. 5‐Fluorouracil (FU), an anti‐cancer drug used in the treat